SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,488,000 | +73.6% | 73,504 | +48.4% | 0.15% | +120.3% |
| Q2 2022 | $1,433,000 | +51.3% | 49,542 | +52.6% | 0.07% | +97.1% |
| Q4 2021 | $947,000 | +17.5% | 32,459 | +7.4% | 0.04% | -16.7% |
| Q3 2021 | $806,000 | +8.5% | 30,230 | +25.4% | 0.04% | +31.2% |
| Q2 2021 | $743,000 | +12.4% | 24,115 | -4.5% | 0.03% | -13.5% |
| Q1 2021 | $661,000 | +41.8% | 25,254 | +36.3% | 0.04% | -5.1% |
| Q4 2020 | $466,000 | -16.9% | 18,525 | -31.2% | 0.04% | -36.1% |
| Q3 2020 | $561,000 | -17.1% | 26,921 | -28.5% | 0.06% | -25.6% |
| Q1 2020 | $677,000 | +165.5% | 37,650 | +250.0% | 0.08% | +290.5% |
| Q4 2019 | $255,000 | -69.8% | 10,756 | -65.0% | 0.02% | -58.8% |
| Q3 2019 | $844,000 | +83.5% | 30,700 | +120.9% | 0.05% | +27.5% |
| Q2 2019 | $460,000 | -43.9% | 13,900 | -40.6% | 0.04% | -67.7% |
| Q1 2019 | $820,000 | +70.1% | 23,400 | +61.4% | 0.12% | -13.3% |
| Q4 2018 | $482,000 | – | 14,500 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |